The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Brain Cancer MORE >>

Larotrectinib demonstrated efficacy across analyses for both pediatric patients and those with brain metastases or primary central nervous system tumors, whether pediatric or adult, with TRK fusions.

Latest JournalAll Journals >>

The Journal of Targeted Therapies in Cancer February 2019
The Journal of Targeted Therapies in Cancer
MORE >>
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.